ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Depomed, Inc. 

7999 Gateway Boulevard
Suite 300
Newark  California  94560  U.S.A.
Phone: 510-744-8000 Fax: 510-744-8001


SEARCH JOBS

Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.

In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

Going forward, the company’s strategy is to continue to identify, license and develop new products that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue.


 Key Statistics


Email: investors@depomed.com
Ownership: Public

Web Site: Depomed, Inc.
Employees:
Symbol: DEPO
 



Industry
Pharmaceutical

Segment
Drug Delivery





 Company News
Depomed, Inc. (DEPO) To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 10/28/2014 7:17:07 AM
Depomed, Inc. (DEPO) Announces Pricing Of Upsized $300 Million Convertible Senior Notes Due 2021 9/5/2014 1:01:31 PM
Depomed, Inc. (DEPO) Summary Judgment Motion Granted In Suit Against FDA Seeking Orphan Drug Exclusivity For Gralise® (Gabapentin) 9/5/2014 12:56:26 PM
Depomed, Inc. (DEPO) Announces Offering Of $230 Million Convertible Senior Notes Due 2021 9/3/2014 4:15:51 PM
Depomed, Inc. (DEPO) To Present At Morgan Stanley 2014 Global Healthcare Conference 8/26/2014 8:58:29 AM
Depomed, Inc. (DEPO) Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 8/19/2014 10:39:25 AM
Depomed, Inc. (DEPO) Reports Second Quarter 2014 Financial Results 8/7/2014 8:46:46 AM
Depomed, Inc. (DEPO) Announces Appointment of R. Scott Shively As Chief Commercial Officer 8/5/2014 7:06:44 AM
Depomed, Inc. (DEPO) To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 7/28/2014 8:31:27 AM
Depomed, Inc. (DEPO) Announces District Court Order In ANDA Litigation 7/18/2014 9:16:50 AM
12345678910...